{"id":331,"date":"2026-02-18T17:20:07","date_gmt":"2026-02-18T15:20:07","guid":{"rendered":"http:\/\/example.test\/?post_type=product&#038;p=331"},"modified":"2026-09-10T10:28:21","modified_gmt":"2026-09-10T07:28:21","slug":"retatrutide-10-mg","status":"publish","type":"product","link":"https:\/\/life-peptide.com\/cs\/product\/retatrutide-10-mg\/","title":{"rendered":"Retatrutid 10 mg"},"content":{"rendered":"<p><strong>Retatrutide 10 mg v Evrop\u011b <\/strong><em>Spole\u010dnost LIFE dod\u00e1v\u00e1 Retatrutide 10 mg jako lyofilizovan\u00fd peptid pro v\u00fdzkumn\u00e9 \u00fa\u010dely s \u010distotou \u226599% a dokumentac\u00ed k dan\u00e9 \u0161ar\u017ei. Objedn\u00e1vky jsou odes\u00edl\u00e1ny z \u00fazem\u00ed EU, p\u0159i\u010dem\u017e v z\u00e1vislosti na m\u00edst\u011b ur\u010den\u00ed jsou k dispozici mo\u017enosti doru\u010den\u00ed Economy, Standard Courier a Air Express.<\/em><\/p>\n<h4><strong>Available in two formats<\/strong><\/h4>\n<p><em>Choose between a conventional lyophilized vial and a dual-chamber cartridge.<\/em><\/p>\n<p>The cartridge keeps Retatrutide and its diluent in separate chambers until activation. This avoids transporting the peptide as a premixed solution and simplifies laboratory preparation by removing the separate liquid-transfer step. Final dual-chamber cartridge concentration: 10 mg in 1 mL. A compatible reusable device is required.<\/p>\n<hr \/>\n<p><strong>Peptid pro \u0159\u00edzen\u00ed hmotnosti 3. generace<\/strong><\/p>\n<p>Retatrutid 10 mg je peptid t\u0159\u00ed agonist\u016f pro v\u00fdzkumn\u00e9 \u00fa\u010dely dod\u00e1van\u00fd v lyofilizovan\u00e9 form\u011b pro laboratorn\u00ed pou\u017eit\u00ed. P\u016fsob\u00ed na receptory GLP-1, GIP a glukagonu a vzbudil siln\u00fd z\u00e1jem v metabolick\u00e9m v\u00fdzkumu, zejm\u00e9na v modelech regulace chuti k j\u00eddlu, zm\u011bn t\u011blesn\u00e9 hmotnosti, glykemick\u00e9 kontroly a energetick\u00e9 bilance.<\/p>\n<p>Retatrutid pat\u0159\u00ed do nov\u011bj\u0161\u00ed t\u0159\u00eddy experiment\u00e1ln\u00edch metabolick\u00fdch peptid\u016f navr\u017een\u00fdch k sou\u010dasn\u00e9mu p\u016fsoben\u00ed na v\u00edce receptorov\u00fdch drah, nikoli pouze k c\u00edlen\u00ed na GLP-1. D\u00edky tomu je obzvl\u00e1\u0161t\u011b relevantn\u00ed pro v\u00fdzkum zam\u011b\u0159en\u00fd na biologii inkretin\u016f, homeost\u00e1zu gluk\u00f3zy, energetickou bilanci a modely obezity nov\u00e9 generace. Vzhledem ke sv\u00e9 \u0161irok\u00e9 receptorov\u00e9 aktivit\u011b je <a href=\"https:\/\/life-peptide.com\/cs\/product\/tirzepatide-10-mg\/\">Tirzepatid<\/a> a jednosm\u011brn\u00e9 slou\u010deniny jako <a href=\"https:\/\/life-peptide.com\/cs\/product\/semaglutide-10-mg\/\">Semaglutid<\/a>, Retatrutide p\u0159edstavuje \u0161ir\u0161\u00ed v\u00fdzkumn\u00fd model s v\u00edce dr\u00e1hami. Pro podrobn\u00e9 srovn\u00e1n\u00ed inkretinov\u00fdch slou\u010denin viz n\u00e1\u0161 <a href=\"https:\/\/life-peptide.com\/cs\/glp-1-metabolic-research-guide\/\">Pr\u016fvodce v\u00fdzkumem metabolismu GLP-1<\/a>.<\/p>\n<p><em>Chcete si v Evrop\u011b zakoupit retatrutid? Spole\u010dnost Life Peptide dod\u00e1v\u00e1 retatrutid vysok\u00e9 \u010distoty pro laboratorn\u00ed v\u00fdzkum a zaji\u0161\u0165uje spolehlivou dopravu po cel\u00e9 EU.<\/em><\/p>\n<hr \/>\n<h4><strong>Co je Retatrutid?<\/strong><\/h4>\n<p>Retatrutid je vy\u0161et\u0159ovac\u00ed <strong>trojit\u00fd agonista peptid<\/strong> vyvinut k aktivaci t\u0159\u00ed kl\u00ed\u010dov\u00fdch receptorov\u00fdch syst\u00e9m\u016f zapojen\u00fdch do regulace metabolismu:<\/p>\n<ul>\n<li>GLP-1 receptor<\/li>\n<li>GIP receptor<\/li>\n<li>glukagonov\u00fd receptor<\/li>\n<\/ul>\n<p>Tento <strong>Semaglutid<\/strong> a <strong>Tirzepatid<\/strong>. Semaglutid c\u00edl\u00ed prim\u00e1rn\u011b na GLP-1, zat\u00edmco Tirzepatid kombinuje aktivitu GLP-1 a GIP. Retatrutid p\u0159id\u00e1v\u00e1 t\u0159et\u00ed slo\u017eku \u2014 <strong>agonismus glukagonov\u00e9ho receptoru<\/strong> \u2014 co\u017e je jeden z d\u016fvod\u016f, pro\u010d vzbudil tolik pozornosti ve v\u00fdzkumu souvisej\u00edc\u00edm s metabolismem a obezitou. Retatrutid je v literatu\u0159e pops\u00e1n jako vyv\u00edjen\u00fd trojn\u00e1sobn\u00fd agonista receptor\u016f hormon\u016f s aktivitou nap\u0159\u00ed\u010d v\u0161emi t\u0159emi cestami.<\/p>\n<h4><strong>Pro\u010d je Retatrutid d\u016fle\u017eit\u00fd ve v\u00fdzkumu metabolismu<\/strong><\/h4>\n<p>Retatrutid je zkoum\u00e1n, proto\u017ee kombinuje <strong>inkretinov\u00e1 signalizace<\/strong> s g<strong>aktivita lucagonov\u00e9ho receptoru<\/strong>, vytv\u00e1\u0159ej\u00edc\u00ed \u0161ir\u0161\u00ed metabolick\u00fd profil ne\u017e standardn\u00ed analogy GLP-1.<\/p>\n<p>V literatu\u0159e byl retatrutid zkoum\u00e1n ve vztahu k:<\/p>\n<ul>\n<li><strong>regulace t\u011blesn\u00e9 hmotnosti a signalizace chuti k j\u00eddlu<\/strong><\/li>\n<li><strong>metabolismus gluk\u00f3zy a glykemick\u00e9 markery<\/strong><\/li>\n<li><strong>energetick\u00e9 v\u00fddaje a vyu\u017eit\u00ed substr\u00e1tu<\/strong><\/li>\n<li><strong>v\u00edcedr\u00e1\u017ekov\u00fd v\u00fdzkum inkretin\u016f<\/strong><\/li>\n<li><strong>modely obezity a metabolick\u00fdch onemocn\u011bn\u00ed nov\u00e9 generace<\/strong><\/li>\n<\/ul>\n<p>V\u011bdci, kte\u0159\u00ed srovn\u00e1vaj\u00ed nov\u011bj\u0161\u00ed metabolick\u00e9 peptidy, \u010dasto zmi\u0148uj\u00ed retatrutid spole\u010dn\u011b se semaglutidem a tirzepatidem, proto\u017ee jeho p\u016fsoben\u00ed p\u0159esahuje r\u00e1mec GLP-1\/GIP a zasahuje do <strong>metabolick\u00e1 modulace t\u0159\u00ed cest<\/strong>. Recenze a p\u0159ehledy jej konzistentn\u011b popisuj\u00ed jako peptid p\u016fsob\u00edc\u00ed na v\u00edce receptor\u016f, kter\u00fd je studov\u00e1n pro l\u00e9\u010dbu obezity a metabolick\u00e9 kontroly, s profilem receptor\u016f \u0161ir\u0161\u00edm ne\u017e d\u0159\u00edv\u011bj\u0161\u00ed inkretinov\u00e1 \u010dinidla.<\/p>\n<h4><strong>Jak funguje Retatrutid<\/strong><\/h4>\n<p>Retatrutid je navr\u017een tak, aby aktivoval t\u0159i receptorov\u00e9 syst\u00e9my zapojen\u00e9 do metabolick\u00e9 kontroly:<\/p>\n<p><strong>Aktivita GLP-1 receptoru<\/strong><\/p>\n<p>Signalizace GLP-1 je spojena se sn\u00ed\u017een\u00edm chuti k j\u00eddlu, opo\u017ed\u011bn\u00fdm vyprazd\u0148ov\u00e1n\u00edm \u017ealudku a podporou inzul\u00ednu z\u00e1vislou na gluk\u00f3ze. To je dr\u00e1ha, kterou v\u011bt\u0161ina v\u00fdzkumn\u00edk\u016f ji\u017e zn\u00e1 z l\u00e1tek, jako je semaglutid.<\/p>\n<p><strong>Aktivita GIP receptoru<\/strong><\/p>\n<p>P\u0159edpokl\u00e1d\u00e1 se, \u017ee signalizace GIP ovliv\u0148uje sekreci inzul\u00ednu, metabolismus \u017eivin a metabolismus tuk\u016f. Ve v\u00fdzkumu.<\/p>\n<p><strong>Aktivita glukagonov\u00e9ho receptoru<\/strong><\/p>\n<p>To je hlavn\u00ed rozd\u00edl. Aktivace glukagonov\u00e9ho receptoru je v sou\u010dasn\u00e9 dob\u011b zkoum\u00e1na z hlediska jej\u00ed role v <strong>energetick\u00fd v\u00fddej, jatern\u00ed metabolismus a regulace t\u011blesn\u00e9 hmotnosti<\/strong>, \u010d\u00edm\u017e je Retatrutid mechanisticky \u0161ir\u0161\u00ed ne\u017e Semaglutid i Tirzepatid.<\/p>\n<p>Spole\u010dn\u011b tyto dr\u00e1hy \u010din\u00ed Retatrutid u\u017eite\u010dnou modelovou slou\u010deninou pro v\u00fdzkum v oblasti <strong>metabolick\u00e1 signalizace zahrnuj\u00edc\u00ed v\u00edce receptor\u016f<\/strong> sp\u00ed\u0161e ne\u017e samotn\u00e1 \u010dinnost inkretin\u016f s jednou dr\u00e1hou. P\u0159ehled samotn\u00e9 Eli Lilly a ned\u00e1vn\u00e1 p\u0159ehledov\u00e1 literatura popisuj\u00ed Retatrutide jako zkouman\u00fd trojit\u00fd agonista p\u016fsob\u00edc\u00ed na receptory GLP-1, GIP a glukagonu, aplikovan\u00fd jednou t\u00fddn\u011b.<\/p>\n<hr \/>\n<h4>Publikovan\u00e9 klinick\u00e9 n\u00e1lezy o Retatrutidu<\/h4>\n<p>Retatrutid p\u0159it\u00e1hl neobvyklou pozornost, proto\u017ee byly hl\u00e1\u0161eny lidsk\u00e9 klinick\u00e9 studie <strong>v\u00fdznamn\u00e9 \u00fa\u010dinky na t\u011blesnou hmotnost, glykemick\u00e9 ukazatele a \u0161ir\u0161\u00ed kardiometabolick\u00e9 parametry<\/strong>. V publikovan\u00e9m v\u00fdzkumu f\u00e1ze 2 u dosp\u011bl\u00fdch s obezitou nebo nadv\u00e1hou experiment\u00e1ln\u00ed retatrutid vyvolal <strong>sn\u00ed\u017een\u00ed hmotnosti v z\u00e1vislosti na d\u00e1vce<\/strong>, p\u0159i\u010dem\u017e skupiny s nejvy\u0161\u0161\u00ed d\u00e1vkou vykazovaly n\u011bkter\u00e9 z nejsiln\u011bj\u0161\u00edch v\u00fdsledk\u016f t\u00fdkaj\u00edc\u00edch se t\u011blesn\u00e9 hmotnosti, jak\u00e9 byly dosud hl\u00e1\u0161eny pro inkretinov\u00e9 l\u00e9\u010divo.<\/p>\n<p>Ned\u00e1vn\u011bji Eli Lilly ozn\u00e1mila data z f\u00e1ze 3 t\u00fdkaj\u00edc\u00ed se obezity z <strong>TRIUMPH-1<\/strong>, kde \u00fa\u010dastn\u00edci ve skupin\u011b s d\u00e1vkou 12 mg ztratili v pr\u016fm\u011bru <strong>28,31 TP3T t\u011blesn\u00e9 hmotnosti b\u011bhem 80 t\u00fddn\u016f<\/strong>, s v\u00fdznamn\u00fdm pod\u00edlem dosahuj\u00edc\u00edm alespo\u0148 <strong>30% \u2013 hubnut\u00ed<\/strong>. Tyto v\u00fdsledky zat\u00edm nejsou stejn\u00e9 jako schv\u00e1len\u00fd obal produktu, ale podstatn\u011b posiluj\u00ed pozici Retatrutidu jako jednoho z nejp\u0159evratn\u011bj\u0161\u00edch metabolick\u00fdch peptid\u016f nov\u00e9 generace ve v\u00fdvoji.<\/p>\n<p>Retatrutid tak\u00e9 prok\u00e1zal klinicky v\u00fdznamn\u00e9 \u00fa\u010dinky ve v\u00fdzkumu diabetu 2. typu. V r\u00e1mci v\u00fdsledk\u016f studie f\u00e1ze 3 TRANSCEND-T2D-1 spole\u010dnosti Lilly sn\u00ed\u017eil Retatrutid <strong>HbA1c p\u0159ibli\u017en\u011b z 1,71 TP3T na 2,01 TP3T<\/strong>, spolu s v\u00fdraznou ztr\u00e1tou hmotnosti, co\u017e posiluje my\u0161lenku, \u017ee jeho profil trojit\u00e9ho agonisty m\u016f\u017ee p\u0159esahovat chu\u0165 k j\u00eddlu a t\u011blesnou hmotnost do \u0161ir\u0161\u00ed metabolick\u00e9 kontroly.<\/p>\n<table>\n<thead>\n<tr>\n<th>Studie<\/th>\n<th>Populace<\/th>\n<th>Hlavn\u00ed zji\u0161t\u011bn\u00ed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>F\u00e1ze 1<\/td>\n<td>Zdrav\u00ed dobrovoln\u00edci<\/td>\n<td>Prok\u00e1zal p\u0159ijateln\u00fd bezpe\u010dnostn\u00ed profil a farmakokinetick\u00e9 vlastnosti podporuj\u00edc\u00ed pod\u00e1v\u00e1n\u00ed jednou t\u00fddn\u011b.<\/td>\n<\/tr>\n<tr>\n<td>Klinick\u00e1 studie obezity f\u00e1ze 2<\/td>\n<td>Dosp\u011bl\u00ed s obezitou nebo nadv\u00e1hou<\/td>\n<td>Pr\u016fm\u011brn\u00fd \u00fabytek hmotnosti se po 48 t\u00fddnech p\u0159i nejvy\u0161\u0161\u00ed zkouman\u00e9 d\u00e1vce p\u0159ibl\u00ed\u017eil hodnot\u011b 24%, p\u0159i\u010dem\u017e do\u0161lo ke zlep\u0161en\u00ed obvodu pasu a n\u011bkolika metabolick\u00fdch parametr\u016f.<\/td>\n<\/tr>\n<tr>\n<td>Klinick\u00e1 studie 2. f\u00e1ze pro diabetes 2. typu<\/td>\n<td>Dosp\u011bl\u00ed s diabetes 2. typu<\/td>\n<td>V\u00fdznamn\u00e9 sn\u00ed\u017een\u00ed hodnoty HbA1c, t\u011blesn\u00e9 hmotnosti a glyk\u00e9mie nala\u010dno ve srovn\u00e1n\u00ed s po\u010d\u00e1te\u010dn\u00edm stavem a placebem.<\/td>\n<\/tr>\n<tr>\n<td>Program TRIUMPH f\u00e1ze 3<\/td>\n<td>Dosp\u011bl\u00ed s obezitou nebo nadv\u00e1hou, v\u010detn\u011b populac\u00ed s diabetem 2. typu a kardiovaskul\u00e1rn\u00edm onemocn\u011bn\u00edm<\/td>\n<td>Z n\u011bkolika studi\u00ed f\u00e1ze 3 byly zve\u0159ejn\u011bny pozitivn\u00ed souhrnn\u00e9 v\u00fdsledky. Ve studii TRIUMPH-1 vyk\u00e1zala skupina u\u017e\u00edvaj\u00edc\u00ed 12 mg pr\u016fm\u011brn\u00e9 sn\u00ed\u017een\u00ed hmotnosti o 28,31 TP3T po 80 t\u00fddnech; studie TRIUMPH-2 a TRIUMPH-3 n\u00e1sledn\u011b vyk\u00e1zaly v\u00fdznamn\u00e9 sn\u00ed\u017een\u00ed hmotnosti u populac\u00ed s diabetem 2. typu a prok\u00e1zan\u00fdm kardiovaskul\u00e1rn\u00edm onemocn\u011bn\u00edm.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h4><strong>Publikovan\u00e9 v\u00fdsledky t\u00fdkaj\u00edc\u00ed se bezpe\u010dnosti a sn\u00e1\u0161enlivosti<\/strong><\/h4>\n<p>Publikovan\u00e9 klinick\u00e9 studie zkoumaj\u00edc\u00ed investiga\u010dn\u00ed Retatrutide nazna\u010duj\u00ed, \u017ee nej\u010dast\u011bji hl\u00e1\u0161en\u00fdmi ne\u017e\u00e1douc\u00edmi \u00fa\u010dinky jsou gastrointestin\u00e1ln\u00ed.<strong>,<\/strong> obzvl\u00e1\u0161t\u011b <strong>nevolnost, pr\u016fjem, zvracen\u00ed a z\u00e1cpa<\/strong>. Ve f\u00e1zi 2 studie obezity publikovan\u00e9 v <em>New England Journal of Medicine<\/em>, tyto ud\u00e1losti se s retatrutidem vyskytovaly \u010dast\u011bji ne\u017e s placebem, byly obecn\u011b <strong>d\u00e1vkov\u011b z\u00e1visl\u00fd<\/strong>, a byly hl\u00e1\u0161eny p\u0159ev\u00e1\u017en\u011b b\u011bhem <strong>obdob\u00ed eskalace d\u00e1vky<\/strong>. V\u011bt\u0161ina byla pops\u00e1na jako <strong>m\u00edrn\u00fd a\u017e st\u0159edn\u00ed<\/strong> v z\u00e1va\u017enosti.<\/p>\n<p>Data z f\u00e1ze 2 rovn\u011b\u017e nazna\u010duj\u00ed, \u017ee sn\u00e1\u0161enlivost m\u016f\u017ee b\u00fdt ovlivn\u011bna v\u00fdchoz\u00ed d\u00e1vkou a harmonogramem nav\u00fd\u0161en\u00ed. Ne\u017e\u00e1douc\u00ed \u00fa\u010dinky na za\u017e\u00edvac\u00ed trakt byly \u010d\u00e1ste\u010dn\u011b zm\u00edrn\u011bny, kdy\u017e se za\u010dalo s navy\u0161ov\u00e1n\u00edm d\u00e1vky. <strong>z 2 mg m\u00edsto<\/strong>, co\u017e je v souladu s \u0161ir\u0161\u00ed t\u0159\u00eddou inkretinov\u00fdch l\u00e9k\u016f, kde se sn\u00e1\u0161enlivost \u010dasto zlep\u0161uje pomalej\u0161\u00edm titrac\u00ed. D\u00e1vkov\u011b z\u00e1visl\u00e9 zv\u00fd\u0161en\u00ed <strong>srde\u010dn\u00ed tep<\/strong> byly tak\u00e9 zaznamen\u00e1ny, p\u0159i\u010dem\u017e vrcholily b\u011bhem soudu a pozd\u011bji klesaly.<\/p>\n<p>Stejn\u011b jako u jin\u00fdch inkretinov\u00fdch p\u0159\u00edpravk\u016f byly ne\u017e\u00e1douc\u00ed \u00fa\u010dinky jedn\u00edm z hlavn\u00edch d\u016fvod\u016f ukon\u010den\u00ed l\u00e9\u010dby v klinick\u00fdch studi\u00edch, zejm\u00e9na p\u0159i vy\u0161\u0161\u00edch d\u00e1vk\u00e1ch. Z tohoto d\u016fvodu se klinick\u00fd profil Retatrutidu obvykle diskutuje nejen z hlediska \u00fa\u010dinnosti p\u0159i hubnut\u00ed, ale tak\u00e9 z hlediska <strong>sn\u00e1\u0161enlivost b\u011bhem eskalace<\/strong>, z.<\/p>\n<h4><strong>Publikovan\u00e9 d\u00e1vkovac\u00ed re\u017eimy pou\u017e\u00edvan\u00e9 ve v\u00fdzkumu Retatrutidu<\/strong><\/h4>\n<p>Publikovan\u00e9 klinick\u00e9 studie s investiga\u010dn\u00edm l\u00e9kem Retatrutide pou\u017e\u00edvan\u00fdm <strong>pod\u00e1v\u00e1n\u00ed podko\u017en\u011b jednou t\u00fddn\u011b s postupn\u00fdm zvy\u0161ov\u00e1n\u00edm d\u00e1vky<\/strong> nam\u00edsto pevn\u00e9ho zah\u00e1jen\u00ed plnou d\u00e1vkou. Ve studii f\u00e1ze 2 o obezit\u011b publikovan\u00e9 v <em>New England Journal of Medicine<\/em>, \u00fa\u010dastn\u00edci byli rozd\u011bleni do n\u011bkolika d\u00e1vkovac\u00edch ramen: <strong>1 mg, 4 mg, 8 mg a 12 mg<\/strong>, p\u0159i\u010dem\u017e n\u011bkter\u00e9 skupiny s vy\u0161\u0161\u00ed d\u00e1vkou za\u010daly s ni\u017e\u0161\u00ed zav\u00e1d\u011bc\u00ed d\u00e1vkou p\u0159ed eskalac\u00ed. Konkr\u00e9tn\u011b studie zahrnovala 4 mg s po\u010d\u00e1te\u010dn\u00ed d\u00e1vkou 2 mg, 4 mg s po\u010d\u00e1te\u010dn\u00ed d\u00e1vkou 4 mg, 8 mg s po\u010d\u00e1te\u010dn\u00ed d\u00e1vkou 2 mg, 8 mg s po\u010d\u00e1te\u010dn\u00ed d\u00e1vkou 4 mg a 12 mg s po\u010d\u00e1te\u010dn\u00ed d\u00e1vkou 2 mg, v\u0161e pod\u00e1v\u00e1no jednou t\u00fddn\u011b po dobu 48 t\u00fddn\u016f.<\/p>\n<p>V praxi to znamen\u00e1, \u017ee publikovan\u00fd v\u00fdzkum Retatrutidu m\u011bl <strong>ne<\/strong> pou\u017e\u00edt jedin\u00fd univerz\u00e1ln\u00ed harmonogram. Program druh\u00e9 f\u00e1ze testoval oboj\u00ed <strong>pomalej\u0161\u00ed eskalace<\/strong> a <strong>rychlej\u0161\u00ed eskalace<\/strong> p\u0159\u00edstupy k dosa\u017een\u00ed stejn\u00e9 udr\u017eovac\u00ed d\u00e1vky, co\u017e je jeden z d\u016fvod\u016f, pro\u010d je studie u\u017eite\u010dn\u00e1 nejen pro hodnocen\u00ed \u00fa\u010dinnosti, ale i pro porovn\u00e1n\u00ed sn\u00e1\u0161enlivosti. Nap\u0159\u00edklad n\u011bkter\u00e9 skupiny s d\u00e1vkou 8 mg za\u010d\u00ednaly na <strong>2 mg a nav\u00fd\u0161eno nahoru<\/strong>, zat\u00edmco jin\u00e9 za\u010daly v <strong>4 mg p\u0159ed dosa\u017een\u00edm stejn\u00e9 c\u00edlov\u00e9 d\u00e1vky<\/strong>. Ram s 12 mg tak\u00e9 pou\u017e\u00edval 2 mg jako po\u010d\u00e1te\u010dn\u00ed d\u00e1vku p\u0159ed eskalac\u00ed.<\/p>\n<p>Studie f\u00e1ze 2 u diabetu 2. typu vyu\u017eila podobnou logiku. \u00da\u010dastn\u00edci dost\u00e1vali jednou t\u00fddn\u011b Retatrutid v d\u00e1vce 0,5 mg, 4 mg, 8 mg nebo 12 mg, p\u0159i\u010dem\u017e n\u011bkter\u00e9 skupiny m\u011bly samostatn\u00e1 ramena s eskalac\u00ed a bez eskalace \u2013 op\u011bt to podtrhuje, \u017ee publikovan\u00fd v\u00fdzkum se siln\u011b zam\u011b\u0159oval na<strong> strategie navy\u0161ov\u00e1n\u00ed d\u00e1vky<\/strong>, nejen na kone\u010dn\u00e9 d\u00e1vce.<\/p>\n<table style=\"height: 231px;\" width=\"771\">\n<thead>\n<tr>\n<th>Publikovan\u00e9 rameno studie<\/th>\n<th align=\"right\">Po\u010d\u00e1te\u010dn\u00ed d\u00e1vka pou\u017eit\u00e1 ve studii<\/th>\n<th align=\"right\">C\u00edlov\u00e1 d\u00e1vka<\/th>\n<th align=\"right\">Frekvence<\/th>\n<th align=\"right\">D\u00e9lka studia<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Obezita f\u00e1ze 2<\/td>\n<td align=\"right\">1 mg<\/td>\n<td align=\"right\">1 mg<\/td>\n<td align=\"right\">jednou t\u00fddn\u011b<\/td>\n<td align=\"right\">48 t\u00fddn\u016f<\/td>\n<\/tr>\n<tr>\n<td>Obezita f\u00e1ze 2<\/td>\n<td align=\"right\">2 mg<\/td>\n<td align=\"right\">4 mg<\/td>\n<td align=\"right\">jednou t\u00fddn\u011b<\/td>\n<td align=\"right\">48 t\u00fddn\u016f<\/td>\n<\/tr>\n<tr>\n<td>Obezita f\u00e1ze 2<\/td>\n<td align=\"right\">4 mg<\/td>\n<td align=\"right\">4 mg<\/td>\n<td align=\"right\">jednou t\u00fddn\u011b<\/td>\n<td align=\"right\">48 t\u00fddn\u016f<\/td>\n<\/tr>\n<tr>\n<td>Obezita f\u00e1ze 2<\/td>\n<td align=\"right\">2 mg<\/td>\n<td align=\"right\">8 mg<\/td>\n<td align=\"right\">jednou t\u00fddn\u011b<\/td>\n<td align=\"right\">48 t\u00fddn\u016f<\/td>\n<\/tr>\n<tr>\n<td>Obezita f\u00e1ze 2<\/td>\n<td align=\"right\">4 mg<\/td>\n<td align=\"right\">8 mg<\/td>\n<td align=\"right\">jednou t\u00fddn\u011b<\/td>\n<td align=\"right\">48 t\u00fddn\u016f<\/td>\n<\/tr>\n<tr>\n<td>Obezita f\u00e1ze 2<\/td>\n<td align=\"right\">2 mg<\/td>\n<td align=\"right\">12 mg<\/td>\n<td align=\"right\">jednou t\u00fddn\u011b<\/td>\n<td align=\"right\">48 t\u00fddn\u016f<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h4>Tyto rozvrhy jsou zahrnuty jako souhrn publikovan\u00e9ho n\u00e1vrhu v\u00fdzkumu a nejsou pokyny k pou\u017eit\u00ed tohoto produktu.<\/h4>\n<hr \/>\n<h4><strong>Pro\u010d je retatrutid jin\u00fd<\/strong><\/h4>\n<p>V\u011bt\u0161ina modern\u00edch metabolick\u00fdch peptid\u016f se zam\u011b\u0159uje na jednu nebo dv\u011b biologick\u00e9 dr\u00e1hy pod\u00edlej\u00edc\u00ed se na regulaci chuti k j\u00eddlu.\u00a0<a href=\"https:\/\/life-peptide.com\/cs\/product\/semaglutide-10-mg\/\">Semaglutid<\/a> aktivuje GLP-1 receptor, \u010d\u00edm\u017e prim\u00e1rn\u011b sni\u017euje chu\u0165 k j\u00eddlu a zpomaluje vyprazd\u0148ov\u00e1n\u00ed \u017ealudku. <a href=\"https:\/\/life-peptide.com\/cs\/product\/tirzepatide-10-mg\/\">Tirzepatid<\/a> kombinuje aktivaci receptor\u016f pro GLP-1 a GIP, co\u017e d\u00e1le zlep\u0161uje kontrolu glyk\u00e9mie a v\u00fdsledky v oblasti t\u011blesn\u00e9 hmotnosti.<\/p>\n<p>Retatrutid tento koncept roz\u0161i\u0159uje sou\u010dasnou aktivac\u00ed t\u0159\u00ed receptor\u016f: GLP-1, GIP a glucagonu. Zat\u00edmco GLP-1 a GIP ovliv\u0148uj\u00ed p\u0159edev\u0161\u00edm regulaci chuti k j\u00eddlu a inzul\u00ednovou signalizaci, aktivita receptoru pro glucagon krom\u011b sn\u00ed\u017een\u00ed p\u0159\u00edjmu potravy z\u0159ejm\u011b zvy\u0161uje energetick\u00fd v\u00fddej.<\/p>\n<p>Tento p\u0159\u00edstup trojit\u00e9ho agonisty odli\u0161uje retatrutid od sou\u010dasn\u011b schv\u00e1len\u00fdch du\u00e1ln\u00edch agonist\u016f a p\u0159inesl jedny z nejv\u011bt\u0161\u00edch \u00fabytk\u016f t\u011blesn\u00e9 hmotnosti, jak\u00e9 byly v klinick\u00e9m v\u00fdvoji zaznamen\u00e1ny. Prob\u00edhaj\u00edc\u00ed studie 3. f\u00e1ze nad\u00e1le hodnot\u00ed jeho dlouhodobou \u00fa\u010dinnost a bezpe\u010dnost.<\/p>\n<h4><strong>Retatrutid vs. Semaglutid vs. Tirzepatid<\/strong><\/h4>\n<p>V\u00fdzkumn\u00edci tyto slou\u010deniny \u010dasto porovn\u00e1vaj\u00ed, proto\u017ee se nach\u00e1zej\u00ed na stejn\u00e9m metabolick\u00e9m spektru, ale nejsou zam\u011bniteln\u00e9.<\/p>\n<p><strong>Retatrutid<\/strong><\/p>\n<ul>\n<li><strong>Trojit\u00fd agonista<\/strong>GLP-1 + GIP + glukagon<\/li>\n<li>Nej\u0161ir\u0161\u00ed profil receptor\u016f z trojice<\/li>\n<li>\u010casto diskutov\u00e1no v souvislosti s <strong>v\u00fdsledky t\u011blesn\u00e9 hmotnosti, regulace chuti k j\u00eddlu a energetick\u00fd v\u00fddej<\/strong><\/li>\n<\/ul>\n<p><a href=\"https:\/\/life-peptide.com\/cs\/product\/tirzepatide-10-mg\/\"><strong>Tirzepatid<\/strong><\/a><\/p>\n<ul>\n<li><strong>Du\u00e1ln\u00ed agonista<\/strong>GLP-1 + GIP<\/li>\n<li>Um\u00edst\u011bn\u00fd mezi Semaglutidem a Retatrutidem v mechanismu<\/li>\n<li>\u0160iroce studov\u00e1no pro <strong>kontrola glyk\u00e9mie a vliv na t\u011blesnou hmotnost<\/strong><\/li>\n<\/ul>\n<p>Podrobn\u00e9 srovn\u00e1n\u00ed aktivity receptor\u016f, publikovan\u00fdch klinick\u00fdch zji\u0161t\u011bn\u00ed a v\u00fdzkumn\u00fdch rozd\u00edl\u016f si m\u016f\u017eete p\u0159e\u010d\u00edst v na\u0161em <a href=\"https:\/\/life-peptide.com\/cs\/retatrutide-vs-tirzepatide\/\">Porovn\u00e1n\u00ed v\u00fdzkumu retatrutidu a tirzepatidu<\/a>.<\/p>\n<p><a href=\"https:\/\/life-peptide.com\/cs\/product\/semaglutide-10-mg\/\"><strong>Semaglutid<\/strong><\/a><\/p>\n<ul>\n<li><strong>Jedin\u00fd agonista<\/strong>GLP-1<\/li>\n<li>Nejzn\u00e1m\u011bj\u0161\u00ed a ne<\/li>\n<li>Spole\u010dn\u00fd referen\u010dn\u00ed bod pro <strong>V\u00fdzkum dr\u00e1hy GLP-1<\/strong><\/li>\n<\/ul>\n<p>Pro v\u00fdzkumn\u00edky, kte\u0159\u00ed sestavuj\u00ed panel metabolick\u00fdch peptid\u016f, je Retatrutid obecn\u011b nejrelevantn\u011bj\u0161\u00ed, pokud je c\u00edlem prozkoumat signalizaci trojit\u00fdch drah, nikoli samotnou standardn\u00ed aktivitu GLP-1.<\/p>\n<hr \/>\n<h4><strong>Vlastnosti produktu<\/strong><\/h4>\n<p>\u010cistota: \u2265 99% (HPLC) s certifik\u00e1tem anal\u00fdzy (COA) pro danou \u0161ar\u017ei<br \/>\nVzhled: b\u00edl\u00fd lyofilizovan\u00fd pr\u00e1\u0161ek<br \/>\nMolekul\u00e1rn\u00ed vzorec: C<sub>221<\/sub>H<sub>342<\/sub>N<sub>46<\/sub>O<sub>68<\/sub><br \/>\nMolekulov\u00e1 hmotnost: 4731,33\u00b11,0<br \/>\nTyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-(\u03b1-Me-Leu)-Leu-Asp-Lys-(diacid-C20-\u03b3-Glu-(AEEA)-Lys)-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH\u2082<br \/>\nVyrobeno v za\u0159\u00edzen\u00edch spl\u0148uj\u00edc\u00edch spr\u00e1vnou v\u00fdrobn\u00ed praxi (GMP) za p\u0159\u00edsn\u00fdch protokol\u016f kontroly kvality.<br \/>\nKa\u017ed\u00e1 \u0161ar\u017ee je po v\u00fdrob\u011b pe\u010dliv\u011b laboratorn\u011b testov\u00e1na (Certifik\u00e1t o anal\u00fdze najdete pod obr\u00e1zky produkt\u016f).<br \/>\nLyofilizov\u00e1no (su\u0161eno mrazem) pro maxim\u00e1ln\u00ed stabilitu a prodlou\u017eenou trvanlivost.<br \/>\nUzav\u0159eno ve steriln\u00edch lahvi\u010dk\u00e1ch, p\u0159ipraveno k rekonstituci.<br \/>\nAplikace: laboratorn\u00ed a analytick\u00fd v\u00fdzkum<\/p>\n<p><strong>\u00dalo\u017ei\u0161t\u011b<\/strong>Neotev\u0159en\u00e9 lyofilizovan\u00e9 lahvi\u010dky jsou nejl\u00e9pe skladov\u00e1ny <strong>chlazen\u00e9 p\u0159i 2\u20138 \u00b0C<\/strong>, co\u017e je metoda skladov\u00e1n\u00ed potvrzen\u00e1 na\u0161\u00edm v\u00fdrobn\u00edm partnerem a vhodn\u00e1 a\u017e po dobu 24 m\u011bs\u00edc\u016f. Preferuje se chlazen\u00ed, proto\u017ee minimalizuje zbyte\u010dn\u00e9 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed b\u011bhem b\u011b\u017en\u00e9 manipulace. Pokud je vy\u017eadov\u00e1no podstatn\u011b del\u0161\u00ed skladov\u00e1n\u00ed, lze zmrazen\u00e9 uchov\u00e1vat i neotev\u0159en\u00e9 lyofilizovan\u00e9 lahvi\u010dky. Po rekonstituci v\u017edy skladujte p\u0159i 2\u20138 \u00b0C a nezmrazujte.<\/p>\n<h4><strong>Nez\u00e1visl\u00e9 ov\u011b\u0159en\u00ed t\u0159et\u00ed stranou<\/strong><\/h4>\n<p>Tato \u0161ar\u017ee pro\u0161la dodate\u010dn\u00fdm analytick\u00fdm ov\u011b\u0159en\u00edm t\u0159et\u00ed stranou prost\u0159ednictv\u00edm spole\u010dnosti Janoshik Analytical<br \/>\nD\u00e1vka: RT10-260410<br \/>\nVnit\u0159n\u00ed \u010distota stanoven\u00e1 metodou HPLC: 99,17%<br \/>\nOv\u011b\u0159en\u00ed t\u0159et\u00ed stranou: Spole\u010dnost 99.57% nez\u00e1visle potvrdila vysokou \u010distotu a shodu slo\u017een\u00ed. <a href=\"https:\/\/verify.janoshik.com\/tests\/153023-Retatrutide_10_mg_LCD4WBFXGVTW\" target=\"_blank\" rel=\"noopener\">Zobrazit ov\u011b\u0159en\u00ed t\u0159et\u00ed stranou<\/a>.<\/p>\n<h4><strong>Rekonstituce a manipulace<\/strong><\/h4>\n<p>Retatrutid je dod\u00e1v\u00e1n v lyofilizovan\u00e9 lahvi\u010dce a m\u011bl by b\u00fdt manipulov\u00e1n s pou\u017eit\u00edm standardn\u00edch postup\u016f pro rekonstituci peptid\u016f vhodn\u00fdch pro v\u00fdzkumn\u00e9 prost\u0159ed\u00ed. Mus\u00ed b\u00fdt rekonstituov\u00e1n s <a href=\"https:\/\/life-peptide.com\/cs\/product\/bac-10-ml\/\">bakteriostatick\u00e1 voda<\/a> p\u0159ed pou\u017eit\u00edm. Peptidy t\u0159\u00eddy GLP-1 se n\u011bkdy rozpou\u0161t\u011bj\u00ed pomalu a vy\u017eaduj\u00ed velmi jemn\u00e9 rozpou\u0161t\u011bn\u00ed, aby se zabr\u00e1nilo p\u011bn\u011bn\u00ed nebo vzniku m\u00edrn\u00e9ho z\u00e1kalu.<\/p>\n<p>Pro dal\u0161\u00ed pokyny k v\u00fdb\u011bru rozpou\u0161t\u011bdla, pl\u00e1nov\u00e1n\u00ed koncentrac\u00ed a skladov\u00e1n\u00ed viz \u00fapln\u00e9 <a href=\"https:\/\/life-peptide.com\/cs\/reconstitution-of-peptides\/\">Pr\u016fvodce rekonstituc\u00ed peptid\u016f<\/a> a <a href=\"https:\/\/life-peptide.com\/cs\/calculator\/\">Kalkula\u010dka rekonstituce<\/a><\/p>\n<hr \/>\n<h4><strong>Vybran\u00e9 v\u00fdzkumn\u00e9 reference<\/strong><\/h4>\n<ul>\n<li>Jastreboff AM a kol. <em>Agonista trojit\u00fdch hormon\u00e1ln\u00edch receptor\u016f retatrutid pro l\u00e9\u010dbu obezity. New England Journal of Medicine<\/em>, 2023.<\/li>\n<li>Coskun T a kol. <em>LY3437943, nov\u00fd trojit\u00fd agonista receptor\u016f pro glukagon, GIP a GLP-1 pro<\/em>, 2022.<\/li>\n<li>Katsi V a kol. <em>Retatrutid \u2014 Hra m\u011bn\u00edc\u00ed l\u00e9k v farmakoterapii obezity<\/em>. p\u0159ehledov\u00fd \u010dl\u00e1nek 2025.<\/li>\n<\/ul>\n<hr \/>\n<h4><strong>\u010casto kladen\u00e9 ot\u00e1zky<\/strong><\/h4>\n<p><strong>Jak\u00fd druh<\/strong><\/p>\n<p>Retatrutid je zkouman\u00fd trojit\u00fd agonista peptid, navr\u017een\u00fd tak, aby aktivoval.<\/p>\n<p><strong>Jak\u00fd je rozd\u00edl mezi Retatrutidem a Semaglutidem?<\/strong>?<\/p>\n<p>Semaglutid c\u00edl\u00ed pouze na GLP-1, zat\u00edmco Retatrutid kombinuje aktivitu receptor\u016f GLP-1, GIP a glukagonu, co\u017e mu d\u00e1v\u00e1 \u0161ir\u0161\u00ed profil metabolick\u00e9 signalizace.<\/p>\n<p><strong>Jak\u00fd je rozd\u00edl mezi Retatrutidem a Tirzepatidem?<\/strong><\/p>\n<p>Tirzepatid je du\u00e1ln\u00ed agonista GLP-1\/GIP. Retatrutid p\u0159id\u00e1v\u00e1 aktivitu glukagonov\u00e9ho receptoru, co\u017e je jeden z hlavn\u00edch d\u016fvod\u016f, pro\u010d upoutal pozornost ve v\u00fdzkumu metabolick\u00fdch onemocn\u011bn\u00ed nov\u00e9 generace.<\/p>\n<p><strong>Retatrutide je spojena s n\u00e1sleduj\u00edc\u00edmi oblastmi v\u00fdzkumu:\n* Hlubok\u00e1 obezita\n* Diabetes mellitus 2. typu\n* Nealkoholick\u00e1 steatohepatitida (NASH)\n* Sn\u00ed\u017een\u00ed hmotnosti<\/strong><\/p>\n<p>Retatrutidum byl ve v\u011bdeck\u00e9 literatu\u0159e studov\u00e1n ve vztahu k v\u00fdsledk\u016fm t\u011blesn\u00e9 hmotnosti, regulaci chuti k j\u00eddlu, glykemick\u00e9 kontrole, inkretinov\u00e9 signalizaci a energetick\u00e9mu metabolismu.<\/p>\n<p><strong>M\u016f\u017ee b\u00fdt retatrutid uchov\u00e1v\u00e1n p\u0159i pokojov\u00e9 teplot\u011b?<\/strong><\/p>\n<p>Pr\u00e1\u0161ek retatrutidu je obecn\u011b stabiln\u011bj\u0161\u00ed p\u0159ed rekonstituc\u00ed ne\u017e po jeho rozpu\u0161t\u011bn\u00ed. Pro dlouhodob\u00e9 laboratorn\u00ed skladov\u00e1n\u00ed se doporu\u010duje chlazen\u00ed podle zam\u00fd\u0161len\u00e9 doby skladov\u00e1n\u00ed.<\/p>\n<p><strong>Jak dlouho lze rekonstituovan\u00fd Retatrutid uchov\u00e1vat?<\/strong><\/p>\n<p>Stabilita rekonstituovan\u00e9ho retatrutidu z\u00e1vis\u00ed na podm\u00ednk\u00e1ch skladov\u00e1n\u00ed a pou\u017eit\u00e9m \u0159edidle. Laboratorn\u00ed praxe obecn\u011b doporu\u010duje skladov\u00e1n\u00ed v chladu a minimalizaci opakovan\u00fdch cykl\u016f oh\u0159\u00edv\u00e1n\u00ed a chlazen\u00ed.<\/p>\n<p><strong>M\u016f\u017ee b\u00fdt Retatrutid po rekonstituci zmrazen?<\/strong><\/p>\n<p>Opakovan\u00e9 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed mohou urychlit degradaci peptid\u016f. Pokud je pro laboratorn\u00ed v\u00fdzkum nutn\u00e9 zmrazen\u00ed, obvykle se doporu\u010duje rozd\u011blit roztok na alikvoty p\u0159ed zmrazen\u00edm.<\/p>\n<p><strong>Rozpou\u0161t\u00ed se retatrutid snadno?<\/strong><\/p>\n<p>Ano. Retatrutid se p\u0159i \u0161etrn\u00e9m zach\u00e1zen\u00ed obvykle snadno rozpou\u0161t\u00ed v bakteriostatick\u00e9 vod\u011b. V\u011bt\u0161inou nen\u00ed nutn\u00e9 jej zb\u011bsile prot\u0159ep\u00e1vat.<\/p>\n<p><strong>M\u011bl by se Retatrutid po p\u0159id\u00e1n\u00ed rozpou\u0161t\u011bdla prot\u0159epat?<\/strong><\/p>\n<p>Jemn\u00e9 krou\u017een\u00ed je obvykle up\u0159ednost\u0148ov\u00e1no p\u0159ed energick\u00fdm t\u0159ep\u00e1n\u00edm, aby se minimalizovalo p\u011bn\u011bn\u00ed a zbyte\u010dn\u00e9 mechanick\u00e9 nam\u00e1h\u00e1n\u00ed peptidov\u00e9ho roztoku.<\/p>\n<p><strong>M\u016f\u017ee b\u00fdt retatrutid p\u0159epravov\u00e1n bez chlazen\u00ed?<\/strong><\/p>\n<p>Ano. N\u00e1\u0161 lyofilizovan\u00fd retatrutid sn\u00e1\u0161\u00ed kr\u00e1tkodob\u00e9 vystaven\u00ed pokojov\u00e9 teplot\u011b l\u00e9pe ne\u017e rekonstituovan\u00fd roztok. Dlouhodob\u00e9mu p\u016fsoben\u00ed tepla by se m\u011blo kdykoli to je mo\u017en\u00e9 vyhnout.<\/p>\n<p><strong>Pro\u010d je retatrutid pova\u017eov\u00e1n za trojit\u00fd agonist?<\/strong><\/p>\n<p>Na rozd\u00edl od samotn\u00fdch agonist\u016f GLP-1 receptoru aktivuje retatrutid receptory GLP-1, GIP a glukagonu sou\u010dasn\u011b, co\u017e z n\u011bj \u010din\u00ed jednoho z prvn\u00edch trojit\u00fdch agonist\u016f, kte\u0159\u00ed vstoupili do pokro\u010dil\u00e9ho klinick\u00e9ho v\u00fdvoje.<\/p>\n<p><strong>\u010c\u00edm se Retatrutid li\u0161\u00ed od d\u0159\u00edv\u011bj\u0161\u00edch GLP-1 peptid\u016f?<\/strong><\/p>\n<p>Retatrutide kombinuje t\u0159i dopl\u0148uj\u00edc\u00ed se metabolick\u00e9 dr\u00e1hy do jedin\u00e9 molekuly. Tento p\u0159\u00edstup s v\u00edce receptory p\u0159inesl jedny z nejv\u011bt\u0161\u00edch v\u00fdsledk\u016f \u00fabytku hmotnosti, jak\u00e9 byly dosud v klinick\u00fdch studi\u00edch zaznamen\u00e1ny.<\/p>\n<p><strong>Mohu si Retatrutide koupit v Evrop\u011b?<\/strong><\/p>\n<p>Ano, Retatrutid 10 mg je k dispozici od spole\u010dnosti LIFE pro \u00fa\u010dely laboratorn\u00edho v\u00fdzkumu. Objedn\u00e1vky jsou odes\u00edl\u00e1ny z EU s doru\u010den\u00edm do v\u011bt\u0161iny evropsk\u00fdch destinac\u00ed. Ka\u017ed\u00e1 \u0161ar\u017ee obsahuje analytickou dokumentaci, p\u0159i\u010dem\u017e u vybran\u00fdch \u0161ar\u017e\u00ed je k dispozici nez\u00e1visl\u00e9 testov\u00e1n\u00ed t\u0159et\u00ed stranou. Dostupn\u00e9 zp\u016fsoby dopravy a dodac\u00ed lh\u016fty se zobrazuj\u00ed b\u011bhem procesu objedn\u00e1vky na z\u00e1klad\u011b va\u0161\u00ed c\u00edlov\u00e9 destinace.<\/p>\n<p><strong>Je tento produkt ur\u010den k lidsk\u00e9mu pou\u017eit\u00ed?<\/strong><\/p>\n<p>Ne. Tento produkt je dod\u00e1v\u00e1n v\u00fdhradn\u011b pro v\u00fdzkumn\u00e9 \u00fa\u010dely a nen\u00ed ur\u010den k lidsk\u00e9 spot\u0159eb\u011b ani k terapeutick\u00e9mu pou\u017eit\u00ed.<\/p>\n<hr \/>\n<h4><strong>Souvisej\u00edc\u00ed v\u00fdzkumn\u00fd kontext<\/strong><\/h4>\n<p>Retatrutid je sou\u010d\u00e1st\u00ed v\u00fdzkumn\u00e9 t\u0159\u00eddy metabolick\u00fdch l\u00e9\u010div s trojit\u00fdm agonistick\u00fdm receptorem GLP-1\/GIP\/glukagon. Pro mechanistick\u00e9 srovn\u00e1n\u00ed s jednoduch\u00fdmi a du\u00e1ln\u00edmi agonisty viz n\u00e1\u0161 <strong><a href=\"http:\/\/example.test\/glp-1-metabolic-research-guide\/\" target=\"_blank\" rel=\"noopener\">Pr\u016fvodce v\u00fdzkumem metabolismu GLP-1<\/a>. <\/strong>Podrobn\u00e9 srovn\u00e1n\u00ed aktivity receptor\u016f, publikovan\u00fdch klinick\u00fdch zji\u0161t\u011bn\u00ed a v\u00fdzkumn\u00fdch rozd\u00edl\u016f si m\u016f\u017eete p\u0159e\u010d\u00edst v na\u0161em <strong><a href=\"https:\/\/life-peptide.com\/cs\/retatrutide-vs-tirzepatide\/\">Porovn\u00e1n\u00ed v\u00fdzkumu retatrutidu a tirzepatidu<\/a>.<\/strong><\/p>\n<p>Proch\u00e1zet v\u0161echny slou\u010deniny v <a href=\"\/cs\/product-category\/metabolic-research\/\"><strong>Kategorie metabolick\u00e9ho v\u00fdzkumu.<\/strong><\/a><\/p>\n<p>V\u00fdzkumn\u00edci porovn\u00e1vaj\u00edc\u00ed aktivaci v\u00edce receptor\u016f mohou tak\u00e9 zkoumat:<\/p>\n<ul>\n<li data-start=\"2635\" data-end=\"2671\"><a href=\"http:\/\/example.test\/product\/tirzepatide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Tirzepatid (du\u00e1ln\u00ed agonista GLP-1\/GIP)<\/a><\/li>\n<li data-start=\"2674\" data-end=\"2702\"><a href=\"http:\/\/example.test\/product\/semaglutide-10-mg\/\" target=\"_blank\" rel=\"noopener\">Semaglutid (agonista receptoru GLP-1)<\/a><\/li>\n<li data-start=\"2674\" data-end=\"2702\"><a href=\"https:\/\/life-peptide.com\/cs\/product\/cagrilintide-5-mg\/\">Kagrilintid<\/a><\/li>\n<li data-start=\"2674\" data-end=\"2702\">Sm\u011bs <a href=\"https:\/\/life-peptide.com\/cs\/product\/blend-cagrilintide-5-mg-retatrutide-10-mg\/\">Cagrilintid + Retatrutid\u00a0<\/a><\/li>\n<li>Sm\u011bs <a href=\"https:\/\/life-peptide.com\/cs\/product\/blend-cagrilintide-5-mg-tirzepatide-10-mg\/\">Kagrilintid + Tirzepatid<\/a><\/li>\n<\/ul>\n<p><strong>POZN\u00c1MKA<\/strong>Toto je pouze pro vzd\u011bl\u00e1vac\u00ed \u00fa\u010dely a nep\u0159edstavuje l\u00e9ka\u0159skou radu.<\/p>\n<p><strong>Z\u0159eknut\u00ed se odpov\u011bdnosti<\/strong><br \/>\nTento produkt je prod\u00e1v\u00e1n pouze pro v\u00fdzkumn\u00e9 \u00fa\u010dely. Nen\u00ed ur\u010den k diagnostice, l\u00e9\u010db\u011b, vyl\u00e9\u010den\u00ed nebo prevenci jak\u00fdchkoli onemocn\u011bn\u00ed. Kupuj\u00edc\u00ed p\u0159eb\u00edr\u00e1 plnou odpov\u011bdnost za \u0159\u00e1dnou manipulaci a pou\u017eit\u00ed.<\/p>","protected":false},"excerpt":{"rendered":"<p>Retatrutid 10 mg je pokro\u010dil\u00e9 v\u00fdzkumn\u00e9 trojit\u00e9 agonistick\u00e9 peptidov\u00e9 \u010dinidlo dod\u00e1van\u00e9 v lyofilizovan\u00e9 form\u011b pro laboratorn\u00ed pou\u017eit\u00ed. Jedn\u00e1 se o jeden z nejpokro\u010dilej\u0161\u00edch zkouman\u00fdch metabolick\u00fdch peptid\u016f, kter\u00fd kombinuje agonismus receptor\u016f GLP-1, GIP a glukagonu v jedn\u00e9 molekule pro v\u00fdzkum regulace chuti k j\u00eddlu, energetick\u00e9ho v\u00fddeje a fyziologie t\u011blesn\u00e9 hmotnosti.<\/p>\n<p>||<\/p>\n<p>\u010cistota \u226599% | N\u00e1kup v Evrop\u011b s dopravou od 5 \u20ac | Mo\u017enost volby dopravy zdarma | P\u0159ij\u00edm\u00e1me platby kartou<\/p>","protected":false},"featured_media":1249,"template":"","meta":[],"product_brand":[],"product_cat":[19],"product_tag":[257,286,248,139,247,258,138,140,246],"class_list":["post-331","product","type-product","status-publish","has-post-thumbnail","product_cat-metabolic-research-peptides","product_tag-appetite-regulation","product_tag-buy-retatrutide","product_tag-energy-balance","product_tag-glp-1-research","product_tag-metabolic-peptide","product_tag-obesity-peptide","product_tag-retatrutide","product_tag-triple-agonist","product_tag-weight-loss-peptide","first","instock","taxable","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"_links":{"self":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product\/331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/media\/1249"}],"wp:attachment":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/media?parent=331"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product_brand?post=331"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product_cat?post=331"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/product_tag?post=331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}